A few months ago, our group performed serial measurements of serum KL-6 in IPF patients after 6 and 12 months of Nintedanib treatment, demonstrating that KL-6 may be a useful prognostic biomarker of IPF progression and response to Nintedanib. The gene discussed is MUC1; the disease is idiopathic pulmonary fibrosis.